ID | 116819 |
Author |
Iwatsuki, N
Sakamoto Hospital
Okada, M
Sakamoto Hospital
|
Keywords | Oral hypoglycemic agents (OHAs)
Imeglimin
type 2 diabetes mellitus (T2DM)
Glucose-stimulated insulin secretion (GSIS)
Treatment-emergent adverse events (TEAEs)
American Diabetes Association (ADA)
|
Content Type |
Journal Article
|
Description | Latest Standards of Medical Care in Diabetes was presented in January 2022. Among oral hypoglycemic agents (OHAs), imeglimin has been topic for a novel agent for type 2 diabetes mellitus (T2DM). Pharmacologically, imeglimin is a cyclic molecule including triazine ring. It has both pharmacological mechanism of increased insulin action and elevation of glucose-stimulated insulin secretion (GSIS). Clinically, it showed HbA1c reduction for 0.46% by monotherapy and 0.56-0.92% by combined therapy with other OHAs. From compared administration of 500mg, 1000mg and 1500mg, 1000mg twice doses would be adequate. No remarkable treatment-emergent adverse events (TEAEs) were found for treatment of imeglimin.
|
Journal Title |
SunText Review of Pharmaceutical Sciences
|
ISSN | 27665232
|
Publisher | SunText Reviews
|
Volume | 3
|
Issue | 1
|
Start Page | 113
|
Published Date | 2022-01-23
|
Rights | This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|
DOI (Published Version) | |
URL ( Publisher's Version ) | |
FullText File | |
language |
eng
|
TextVersion |
Publisher
|
departments |
Medical Sciences
|